Blood Tests to Study Clotting Risk in Myeloproliferative Neoplasms
Blood samples from adults with myeloproliferative neoplasms are studied to link clotting risk.
Plain-language title generated from the registry record
Registry title: Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Key facts
- Where
- Angers, Bayonne, Bordeaux, Brest, Dax, Libourne, Mont-de-Marsan, and Pessac, FranceSee the 11 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed polycythemia vera (PV) or essential thrombocythemia (ET) who carry a JAK2V617F mutation and have not yet started treatment to lower blood counts.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Polycythemia vera (PV) or essential thrombocythemia (ET), enrolled at diagnosis or within the year after diagnosis (2016 WHO criteria; bone marrow biopsy is optional).
- Earlier treatment
- No cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib or other chemotherapy) at the time of blood sampling. Enrolment must come before such treatment starts.
- Biomarker or test result
- JAK2V617F mutation required.
Main reasons for not taking part
- PV or ET without a JAK2V617F mutation
- Cytoreductive treatment at the time of blood sampling
- Person under judicial safeguards, trusteeship or curatorship
- Person unable to give consent, or not cooperative
- Another clinical study in the 30 days before inclusion
Read by machine on 12 November 2026.
Where in France
- CHU d'Angers, Service Maladies du SangAngers, FranceContact: François BOYERTaking people
- CH de Bayonne, Service Hématologie CliniqueBayonne, FranceContact: Harmony LEROYTaking people
- CHU de Bordeaux, Service Médecine Interne et Maladies InfectieusesBordeaux, FranceContact: Pierre DUFFAUTaking people
- Institut Bergonié, Service Hématologie CliniqueBordeaux, FranceContact: Etienne GABRIELTaking people
- CHU de Brest, Service Hématologie CliniqueBrest, FranceContact: Eric LIPPERTTaking people
- CH de Dax, Service Hématologie CliniqueDax, FranceContact: Clémentine SALVADOTaking people
- CH de Libourne, Service Hématologie CliniqueLibourne, FranceContact: Diane LARATaking people
- CH de Mont de Marsan, Service OncologieMont-de-Marsan, FranceContact: Samia MADENETaking people
- CHU de Bordeaux, Service Hématologie BiologiePessac, FranceContact: Chloé JAMESTaking people
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie CellulairePessac, FranceContact: Clémence MEDIAVILLATaking people
- CHU de Bordeaux, Service Médecine InternePessac, FranceContact: Jean-François VIALLARDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT05839717
- Record updated
- 17 December 2024
- Original description
Myeloproliferative Neoplasms (MPN) are associated with an increased risk of thrombosis. Platelets, red blood cells (RBC), leukocytes and endothelial cells are involved in these complications. An association with the JAK2V617F allele burden assessed in leukocytes has also been suggested. In some patients the allele burden measured in platelets and red blood cells is higher than the one determined in leukocytes. Our project aims at associating the risk of thrombosis with the allele burden determined in the cell populations (platelets, red blood cells, granulocytes and endothelial cells) and identifying high-risk clonality profiles.Read full original descriptionShow less
Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Myeloproliferative Neoplasms (MPN) are associated with an increased risk of thrombosis. Platelets, red blood cells (RBC), leukocytes and endothelial cells are involved in these complications. An association with the JAK2V617F allele burden assessed in leukocytes has also been suggested. In some patients the allele burden measured in platelets and red blood cells is higher than the one determined in leukocytes. Our project aims at associating the risk of thrombosis with the allele burden determined in the cell populations (platelets, red blood cells, granulocytes and endothelial cells) and identifying high-risk clonality profiles.
Inclusion: Adult patient (age ≥ 18 years); Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional), before introduction of a cytoreductive treatment; Patient carrying a JAK2V617F mutation; Subject registered with a social security scheme; Written informed consent obtained; Acceptance of inclusion in the FIMBANK registry (specific consent form needed).
Exclusion: Patient with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib or other chemotherapy) at the time of blood sampling; Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion; ET or PV Patient not carrying a JAK2V617F mutation; Person under judicial safeguards, trustee or curatorship; Person unable to give her consent; Non-cooperative person.